Ahmed Elkashef

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls
    Ahmed M Elkashef
    Clinical Trials Branch, NIDA, Bethesda, MD 20892 9551, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:145-8. 2002
  2. ncbi Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E
    A M Elkashef
    Medications Development Division, National Institute on Drug Abuse, Bethesda, MD 20892 9551, USA
    Schizophr Bull 25:731-40. 1999
  3. pmc Pharmacotherapy of methamphetamine addiction: an update
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:31-49. 2008
  4. pmc Marijuana neurobiology and treatment
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:17-29. 2008
  5. ncbi Biotechnology and the treatment of addictive disorders: new opportunities
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMC, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, Maryland 20892 9551, USA
    BioDrugs 21:259-67. 2007
  6. ncbi Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
  7. ncbi The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity
    Ahmed Elkashef
    Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Addiction 102:107-13. 2007
  8. ncbi Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
  9. ncbi Biological markers of cocaine addiction: implications for medications development
    Ahmed Elkashef
    Division of Treatment, Research and Development DTR and D, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Addict Biol 8:123-39. 2003
  10. ncbi 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography
    A M Elkashef
    Clinical Trials Branch, DTRD NIDA, NIH, 6001 Executive Blvd, Room 4123, MSC 551, Bethesda, MD, 20892 9551, USA
    Psychiatry Res 100:1-11. 2000

Detail Information

Publications36

  1. ncbi Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls
    Ahmed M Elkashef
    Clinical Trials Branch, NIDA, Bethesda, MD 20892 9551, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:145-8. 2002
    ..This study shows that DA can impair the mitochondria membrane potential but that mechanism may not be evident in schizophrenia...
  2. ncbi Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E
    A M Elkashef
    Medications Development Division, National Institute on Drug Abuse, Bethesda, MD 20892 9551, USA
    Schizophr Bull 25:731-40. 1999
    ..Since then many preclinical and clinical studies have investigated this possibility. These studies suggest that free radicals are probably involved in the pathogenesis of TD and that vitamin E could be efficacious in its treatment...
  3. pmc Pharmacotherapy of methamphetamine addiction: an update
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:31-49. 2008
    ..Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies...
  4. pmc Marijuana neurobiology and treatment
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:17-29. 2008
    ..The next few years looking promising for translational research efforts to make treatment widely accessible to patients with marijuana dependence...
  5. ncbi Biotechnology and the treatment of addictive disorders: new opportunities
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMC, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, Maryland 20892 9551, USA
    BioDrugs 21:259-67. 2007
    ..The main focus of this review is on the development of immunotherapy for stimulants and nicotine addiction as a model highlighting the current status of the science and potential emerging discoveries and development...
  6. ncbi Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
    ....
  7. ncbi The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity
    Ahmed Elkashef
    Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Addiction 102:107-13. 2007
    ..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously...
  8. ncbi Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
    ..The contrast of this result to earlier, promising preclinical and human pilot data could be due to factors associated with sample size, patient characteristics, dose, or poor predictive validity of preclinical models...
  9. ncbi Biological markers of cocaine addiction: implications for medications development
    Ahmed Elkashef
    Division of Treatment, Research and Development DTR and D, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Addict Biol 8:123-39. 2003
    ..Merging the biology within medications studies of cocaine abusers could prove useful for targeting specific pharmacological agents to subgroups of patients, prediction of response to medication and relapse to use...
  10. ncbi 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography
    A M Elkashef
    Clinical Trials Branch, DTRD NIDA, NIH, 6001 Executive Blvd, Room 4123, MSC 551, Bethesda, MD, 20892 9551, USA
    Psychiatry Res 100:1-11. 2000
    ..The 18F-DOPA PET technique proved to be useful and sensitive in detecting changes in dopamine metabolism in patients with schizophrenia in vivo. The results of this study provide evidence of an aberrant dopamine system in schizophrenia...
  11. pmc Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals
    Roberta Kahn
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, 6001 Executive Blvd, Bethesda, MD 20892, USA
    Drug Alcohol Depend 103:59-64. 2009
    ..Baclofen's potential as a relapse prevention agent was not tested by the current design, but may be a useful target for future studies...
  12. pmc Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants
    Louis Cantilena
    Division of Clinical Pharmacology and Medical Toxicology, Uniformed Services University of Health Sciences, Bethesda, MD, USA
    J Addict Med 6:265-73. 2012
    ..We investigated the safety of the interaction of atomoxetine with cocaine and also whether cognitive function was affected by atomoxetine during short-term administration...
  13. pmc Selegiline transdermal system (STS) as an aid for smoking cessation
    Roberta Kahn
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, MD 20892, USA
    Nicotine Tob Res 14:377-82. 2012
    ..We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI...
  14. pmc Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial
    Ahmed Elkashef
    National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA
    Addiction 107:1297-306. 2012
    ..Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction...
  15. ncbi Medication development for addictive disorders: the state of the science
    Frank J Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Rm 4133, MSC 9551, Bethesda, MD 20892 9551, USA
    Am J Psychiatry 162:1432-40. 2005
    ..Potential medications that modulate these mechanisms are highlighted...
  16. ncbi Intravenous cocaine and QT variability
    Mark C P Haigney
    Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Cardiovasc Electrophysiol 17:610-6. 2006
    ..Dynamic instability in cardiac repolarization may contribute to drug-induced arrhythmogenesis. We hypothesized that intravenous cocaine would significantly destabilize repolarization as measured by QT variability...
  17. ncbi Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during phase 1 clinical trials
    Louis R Cantilena
    Division of Clinical Pharmacology and Medical Toxicology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Contemp Clin Trials 28:695-704. 2007
    ..The potential to obscure important signals for hepatotoxicity during Phase 1 research may be higher in the CE study population...
  18. doi Interventions for HIV and hepatitis C virus infections in recreational drug users
    Jag H Khalsa
    Medical Consequences Branch and 2Clinical Trials Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA
    Clin Infect Dis 50:1505-11. 2010
    ....
  19. ncbi Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Addiction 100:91-101. 2005
    ..Pooling data from these small pilot trials into four major drug classes permitted data exploration for treatment and covariate effects with increased sample size...
  20. pmc Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs
    Jag H Khalsa
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, MD 20892, USA
    Am J Addict 19:96-100. 2010
    ....
  21. ncbi Transdermal selegiline and intravenous cocaine: safety and interactions
    Elisabeth J Houtsmuller
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Medical Center, 5510 Nathan Shock Drive, Baltimore, MD 21224 6823, USA
    Psychopharmacology (Berl) 172:31-40. 2004
    ..Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine...
  22. ncbi The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study day
    Eugene Somoza
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Drug Alcohol Depend 93:132-40. 2008
    ....
  23. ncbi Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence
    Domenic A Ciraulo
    Division of Psychiatry, Boston University School of Medicine, VA Boston Healthcare System Medication Development Research Unit MDRU, Boston, MA, USA
    Addiction 100:12-22. 2005
    ..The two studies presented here were conducted to assess the efficacy of paroxetine, pentoxifylline, riluzole, venlafaxine and pramipexole as medications for the treatment of cocaine dependence...
  24. ncbi Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence
    Deborah B Leiderman
    Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Addiction 100:1-11. 2005
    ....
  25. ncbi Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers
    Jennifer L Donovan
    Laboratory of Drug Disposition and Pharmacogenetics, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina MUSC, Charleston, South Carolina, USA
    Clin Pharmacokinet 44:753-65. 2005
    ..To determine if modafinil, a putative treatment for cocaine dependence, influences the pharmacokinetics of intravenous cocaine in otherwise healthy cocaine-dependent volunteers...
  26. ncbi Safety of intravenous methamphetamine administration during treatment with bupropion
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Psychopharmacology (Berl) 182:426-35. 2005
    ..Methamphetamine dependence is a growing problem for which no medication treatments have proven effective...
  27. ncbi Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90024, USA
    Neuropsychopharmacology 31:1537-44. 2006
    ..Importantly, these data provide a rationale for the evaluation of bupropion in the treatment of methamphetamine dependence...
  28. ncbi A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California at Los Angeles, USA
    Pharmacol Biochem Behav 82:704-11. 2005
    ..The available data suggest that selegiline is likely to be safe if used as a pharmacotherapy for methamphetamine dependence...
  29. ncbi A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program
    Malcolm S Reid
    New York University School of Medicine, New York, NY 10010, USA
    Subst Abus 26:5-14. 2005
    ..05) and self-rated severity of cocaine dependence (p < 0.05) in the placebo group. This pilot study does not support the effectiveness of mecamylamine for the treatment of cocaine dependence in methadone or LAAM maintained patients...
  30. ncbi A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence
    Bankole A Johnson
    Department of Psychiatric Medicine, University of Virginia, P O Box 800623, Charlottesville, VA 22908 0623, USA
    Drug Alcohol Depend 84:256-63. 2006
    ..04). These results suggest the possibility of a non-linear dose-response function, with evidence supporting efficacy for the 4.0 mg group...
  31. ncbi A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence
    Theresa Winhusen
    Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Drug Alcohol Depend 91:141-8. 2007
    ..The potential efficacy of tiagabine for treating cocaine dependence is suggested by both pre-clinical research and two small clinical trials...
  32. ncbi A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence
    Theresa Winhusen
    Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Drug Alcohol Depend 91:205-12. 2007
    ..The potential efficacy of reserpine, a dopamine depletor, for treating cocaine dependence is suggested by both pre-clinical research and a small clinical trial...
  33. ncbi A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence
    S Paul Berger
    Cincinnati VA UC NIDA MDRU, VA Medical Center, Cincinnati, OH, USA
    Addiction 100:58-67. 2005
    ..To conduct a preliminary evaluation of the safety and efficacy of reserpine, gabapentin or lamotrigine versus an unmatched placebo control as a treatment for cocaine dependence...
  34. ncbi Modafinil and cocaine interactions
    Robert Malcolm
    Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Drug Alcohol Abuse 32:577-87. 2006
    ..Modafinil significantly dampened scores on Visual Analog Scale measures as compared to baseline cocaine conditions. No significant alterations in labs occurred. Further outpatient trials of modafinil appear to be warranted...
  35. ncbi Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned
    Kyle M Kampman
    Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    Addiction 100:102-10. 2005
    ....
  36. ncbi A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments
    Theresa M Winhusen
    Cincinnati VA UC NIDA MDRU, VA Medical Center, Cincinnati, OH, USA
    Addiction 100:68-77. 2005
    ..To conduct a preliminary evaluation of the safety and efficacy of tiagabine, sertraline or donepezil versus an unmatched placebo control as a treatment for cocaine dependence...